Hims & Hers Health (82W) Price & Analysis

Compare

36 Followers

82W Stock Chart & Stats

€13.60

-€0.66(-2.50%)

At close: Jan 08 4:00 PM EST

€13.60

-€0.66(-2.50%)

Day’s Range― - ―

52-Week Range€11.82 - €61.70

Previous CloseN/A

Volume1.67K

Average Volume (3M)2.94K

Market Cap

$3.10B

Enterprise Value€4.52B

Total Cash (Recent Filing)$577.49M

Total Debt (Recent Filing)$1.26B

Price to Earnings (P/E)56.9

Beta1.98

Next Earnings

May 11, 2026

EPS Estimate

0.02

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.07

Shares Outstanding219,561,140

10 Day Avg. Volume3,249

30 Day Avg. Volume2,943

Financial Highlights & Ratios

PEG Ratio-33.00

Price to Book (P/B)13.50

Price to Sales (P/S)3.11

P/FCF Ratio98.76

Enterprise Value/Market Cap1.46

Enterprise Value/Revenue1.93

Enterprise Value/Gross Profit2.76

Enterprise Value/Ebitda26.63

Forecast

1Y Price Target

$19.99

Price Target Upside46.99% Upside

Rating ConsensusHold

Number of Analyst Covering13

EPS Forecast (FY)0.49

Revenue Forecast (FY)$2.33B

Bulls Say, Bears Say

Bulls Say

Diagnostic-led Product ExpansionShift toward diagnostic-led experiences that combine at-home lab testing, provider interactions, and new therapies can accelerate product launches and diversify revenue beyond legacy categories.

International Growth Through AcquisitionAcquisition of a large international business and focused cross-border expansion are positioned to scale the platform and materially increase the company's international revenue base.

Personalization And Data-driven CareExpansion of data-driven personalization across the care journey using wearables, broader data vectors, and AI-enhanced matching can improve treatment effectiveness and support stronger customer retention.

Bears Say

Dependence On Weight-loss FranchiseHeavy reliance on weight-loss products leaves the business exposed to intensifying competition and channel shifts that could erode demand and slow overall revenue growth.

Margin Pressure From Investments And Operational ChangesIncreased spending on international expansion and infrastructure, together with shipment timing changes tied to regulatory sourcing, is likely to compress gross margins and pressure near-term profitability.

Regulatory And Legal RiskOngoing litigation and uncertainty around compounded injectable therapies create the potential for regulatory actions or investigations that could disrupt operations and damp investor confidence.

Hims & Hers Health News

Mixed options sentiment in Hims and Hers Health with shares down 1.04%

Mixed options sentiment in Hims and Hers Health (HIMS), with shares down 16c near $15.71. Options volume roughly...

15h ago

HIMS

Mixed options sentiment in Hims and Hers Health with shares down 3.5%

Mixed options sentiment in Hims and Hers Health (HIMS), with shares down 57c near $15.88. Options volume relatively...

1d ago

HIMS

FDA warns 30 telehealth companies against illegal marketing of compounded GLP-1s

The U.S. Food and Drug Administration announced the issuance of 30 warning letters to telehealth companies for making...

4d ago

LLY

NVO

Mixed options sentiment in Hims and Hers Health with shares down 1.49%

Mixed options sentiment in Hims and Hers Health (HIMS), with shares down 24c near $16.23. Options volume relatively...

4d ago

HIMS

Midday Fly By: Target earnings hit the mark, Elliott invests $1B in Pinterest

The three top indexes were each down nearly 1.5% near noon following fresh military strikes and widening hostilities...

4d ago

Hims’ partner to reintroduce GLP-1 pill pulled from market, Endpoints News says

Hims’ pharmacy partner will reintroduce a compounded pill version of GLP-1 drug Wegovy that was pulled from the...

4d ago

HIMS

Can Hims & Hers Overcome FDA’s GLP-1 Crackdown?

The U.S. Food and Drug Administration (FDA) cracked down on GLP-1 copycats in February 2026. Despite this and...

4d ago

LLY

NVO

Hims & Hers Stock (HIMS) Surged 13.5% — Could More Gains Be Ahead?

Shares of Hims & Hers Health ($HIMS) were up by 13.5% on Monday. The surge came after comments...

4d ago

HIMS

Mixed options sentiment in Hims and Hers Health with shares down 5.42%

Mixed options sentiment in Hims and Hers Health (HIMS), with shares down 84c near $14.76. Options volume roughly...

8d ago

HIMS

Hims & Hers price target lowered to $25 from $48 at Barclays

Barclays lowered the firm’s price target on Hims & Hers to $25 from $48 and keeps an Overweight...

11d ago

HIMS

Midday Fly By: Home Depot reports Q4 beat, AMD and Meta expand partnership

The major averages were broadly higher near noon in a bounce-back from yesterday’s declines, though sentiment remains fragile...

11d ago

AMD

Qualcomm, Booking Holdings upgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

11d ago

DPZ

HIMS Earnings: Hims & Hers Health Stock Down after Mixed Q4 Results

Hims & Hers Health ($HIMS) stock declined in the after-hours trading after reporting mixed fourth-quarter and full‑year 2025 results....

11d ago

HIMS

Is HIMS Stock a Buy Ahead of Earnings? Options Traders Brace for 15% Price Swing

Hims & Hers ($HIMS) will release its fourth-quarter fiscal 2025 results after market close on February 23. Analysts...

12d ago

HIMS

82W FAQ

What was Hims & Hers Health’s price range in the past 12 months?

Hims & Hers Health lowest stock price was €11.81 and its highest was €61.70 in the past 12 months.

What is Hims & Hers Health’s market cap?

Hims & Hers Health’s market cap is $3.10B.

When is Hims & Hers Health’s upcoming earnings report date?

Hims & Hers Health’s upcoming earnings report date is May 11, 2026 which is in 65 days.

How were Hims & Hers Health’s earnings last quarter?

Hims & Hers Health released its earnings results on Feb 23, 2026. The company reported €0.068 earnings per share for the quarter, beating the consensus estimate of €0.034 by €0.034.

Is Hims & Hers Health overvalued?

According to Wall Street analysts Hims & Hers Health’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Hims & Hers Health pay dividends?

Hims & Hers Health does not currently pay dividends.

What is Hims & Hers Health’s EPS estimate?

Hims & Hers Health’s EPS estimate is 0.02.

How many shares outstanding does Hims & Hers Health have?

Hims & Hers Health has 219,561,140 shares outstanding.

What happened to Hims & Hers Health’s price movement after its last earnings report?

Hims & Hers Health reported an EPS of €0.068 in its last earnings report, beating expectations of €0.034. Following the earnings report the stock price went up 1.527%.

Which hedge fund is a major shareholder of Hims & Hers Health?

Currently, no hedge funds are holding shares in DE:82W

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Hims & Hers Health Stock Smart Score

Underperform

Fundamentals

Return on Equity

25.23%

Trailing 12-Months

Asset Growth

197.28%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Hims & Hers Health

Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products, primarily focusing on wellness, sexual health and wellness, skincare, and hair care. The company's curated non-prescription products include vitamin C, melatonin, biotin, and collagen protein supplements in the wellness category; moisturizer, serums, and face wash in the skincare category; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness category; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care category. In addition, it offers medical consultation services, as well as health and wellness products through wholesale partners. The company is based in San Francisco, California.

Hims & Hers Health (82W) Earnings & Revenues

Historic Earnings Reports

82W Earnings Call

Q4 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call conveyed strong commercial momentum and financial improvement: robust top-line growth (Q4 +28%, FY +59%), expanding profitability (adjusted EBITDA +~80%), growing subscriber base (>2.5M) and meaningful cash generation. Management emphasized rapid product launches, diagnostic and hormonal early successes, and aggressive international expansion via acquisitions. Offsetting these positives are near-term headwinds from fulfillment timing ($65M Q1 revenue timing impact), margin pressure from investments and international mix, regulatory uncertainty around compounded GLP-1s, and sizable acquisition-related commitments. Overall, fundamentals and strategic investments appear to outweigh the near-term risks, though execution and regulatory outcomes will be key to sustaining the trajectory.View all DE:82W earnings summaries

82W Revenue Breakdown

96.60% Online

3.40% Wholesale

82W Stock 12 Month Forecast

Average Price Target

€19.99

▲(46.99% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"9":"€9","56":"€56","20.75":"€20.8","32.5":"€32.5","44.25":"€44.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":41.31505824,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€41.32</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19.990463075500003,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€19.99</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10.75912975,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€10.76</span>\n  </div></div>","useHTML":true}}],"tickPositions":[9,20.75,32.5,44.25,56],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14,16.101158326153847,18.202316652307694,20.303474978461537,22.404633304615384,24.50579163076923,26.606949956923074,28.70810828307692,30.809266609230768,32.91042493538461,35.01158326153846,37.112741587692305,39.21389991384615,{"y":41.31505824,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14,14.460804851961539,14.921609703923078,15.382414555884615,15.843219407846155,16.304024259807694,16.76482911176923,17.225633963730772,17.68643881569231,18.147243667653846,18.608048519615387,19.068853371576925,19.529658223538465,{"y":19.990463075500003,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14,13.750702288461538,13.501404576923077,13.252106865384615,13.002809153846155,12.753511442307692,12.50421373076923,12.25491601923077,12.005618307692307,11.756320596153845,11.507022884615385,11.257725173076922,11.008427461538462,{"y":10.75912975,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":42.38,"date":1740787200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":29.8,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 16</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":29.24,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 16</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":50.9,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 17</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":39.95,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 13</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":55.28,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":36.56,"date":1756684800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":48.04,"date":1759276800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 13</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":41.15,"date":1761955200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 18</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":33.16,"date":1764547200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 15</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":29,"date":1767225600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 13</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":23.1,"date":1769904000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":14,"date":1772323200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >